QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy

European Journal of Clinical Pharmacology

Volumn 58, Issue 3, 2002, Pages 223-224

  LLerena, Adrin ^a,b   Berecz, Roland ^a,b   De La Rubia, Alfredo ^a,b   Dorado, Pedro ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Psychiatric Hospital   (Spain)

Author keywords

Debrisoquine; Haloperidol; QTc

Indexed keywords

4 HYDROXYDEBRISOQUINE; CYTOCHROME P450 2D6; DEBRISOQUINE; DROPERIDOL; HALOPERIDOL; NEUROLEPTIC AGENT; PIMOZIDE; SULPIRIDE; THIORIDAZINE;

ADULT; AGED; ANALYTIC METHOD; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; HEART ARRHYTHMIA; HEREDITY; HUMAN; LETTER; LONG QT SYNDROME; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC RATE; MONOTHERAPY; PHENOTYPE; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; TORSADE DES POINTES; URINALYSIS; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GENETICS; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOSIS; URINE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPSYCHOTIC AGENTS, BUTYROPHENONE; DEBRISOQUIN; FEMALE; HALOPERIDOL; HUMAN; LONG QT SYNDROME; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGE; PSYCHOTIC DISORDERS; SUPPORT, NON-U.S. GOV'T; ANTIPSYCHOTIC AGENTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MIDDLE AGED;

EID: 0035984811     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0452-7     Document Type: Letter

References (11)

1. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
2. Antipsychotics and the risk of sudden cardiac death
3. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death
4. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review
5. Torsade de pointes and low-dose oral haloperidol
6. Interethnic differences in drug metabolism: Influence of sex-related and environmental factors on debrisoquine hydroxylation phenotype
7. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
8. CYP2D6 polymorphism in psychiatric patients during haloperidol monotherapy
9. Debrisoquine oxidation polymorphism in a Spanish population
10. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
11. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population